TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean reaction time change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of lapses in PVT change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aggregate PVT score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stanford Sleepiness Scale change
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Noordsy-Dahle Subjective Experience Scale change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Two-point discrimination test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left/right discrimination (Lateralization)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in morphology of cutaneous warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Effectiveness of transperineal ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free survival (PFS) at 24 months
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients receiving a single dose of RAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of participants that drop-out
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of rebleeding within 7 days of successful endoscopic hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of rebleeding within 30 days of successful endoscopic hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Severity of atrophic acne scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Brain activation during Monetary Incentive Delay Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain connectivity during resting-state functional neuroimaging protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Height-adjusted total liver volume (htTLV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VCI scale from intubator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VCI scale from observer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Time in Range (TIR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics (PK) of IV dose of omadacycline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics (PK) of PO dose of omadacycline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DFU wound healing rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to DFU healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of infusion reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of product-related infections
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of product-related infections
Endpoint domain: Adverse events/effects
Primary endpoint: Evidence of alloimmunization via anti-HLA antibodies
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of graft vs. host disease
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of graft vs. host disease
Endpoint domain: Adverse events/effects
Primary endpoint: Anti-Mullerian Hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Psychological well-being scale (PWS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: facial bone thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Left Ventricular Global Longitudinal Strain (LVGLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Evaluation of Safety
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Duration of Suctioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Duration of Suctioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of ≥ grade 3 skin toxicity adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Local control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mother-To-Infant Bonding
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in the cytokine milieu in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Functional Assessment of Stroke
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: IBS Symptom Severity Scale (IBS-SSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of physiologically non-significant lesions observed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under curve of the PMCA for early diagnosis of PD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite total of HF events and cardiovascular (CV) death
Endpoint domain: Mortality/survival
Primary endpoint: CES-DC Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PIPP-R Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunohistochemical expression of Glypican-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who complete training
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Family-Based Treatment Knowledge Assessment (FBT-KA) Score at Post-Training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in production of IL-6 in monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Alcohol Dependence/Craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Synaptic Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to relapse
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Urine toxicology post treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with mRS score ≤1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological complete response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective cognitive difficulties
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Improvement in hyperactivity sub-score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in inattentiveness sub-score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of pregnancy after FSS
Endpoint domain: Mortality/survival
Primary endpoint: Knee extension and flexion isometric strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of direction sprint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corrected gestational age at the time of acquisition of full oral feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Auditory verbal hallucination severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interleukin 6 (pg/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fasting insulin (uIU/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: High sensitivity C-reactive protein (mg/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Validation of staging system in ALS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dopamine serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serotonin serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child resting brain function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Result of orthopedic treatment and osteosynthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Modified Function Reach (MFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight of cord blood collection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life Questionnaire in Autism
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduced blood cholesterol and triglycerides levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduced blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Normalized blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduced BMI and visceral obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: acute insomnia effects
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: postpartum insomnia effects
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Recurrent caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Technical survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Photonumeric cellulite severity scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Resting Motor Threshold (RMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arabic version Conners' Parent Rating Scale - Revised Long form
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain reduction after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge change related to dementia prevention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Brain-derived neurotropic factor (BDNF) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage/Proportion of subjects who achieve at least a one-grade reduction in the IGA Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants with Acute GU and GI toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Late GU and GI toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Evaluation of patient-reported quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time in glucose range 70 - 180mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diagnosis of Parkinson's disease or dementia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visualization and characterization of breast abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Reduction in Overstimulation Sensation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recovery Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Thermal Comfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of subjects with significant hepatic fat change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Brain MRI volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Collected tumor samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Collected Blood Samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: HDV serology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HDV viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of stage III colon cancer
Endpoint domain: Mortality/survival
Primary endpoint: 28-day mortality due to sepsis
Endpoint domain: Mortality/survival
Primary endpoint: Time to achieve transaminases within 1.5 times ULN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants reporting expected adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participant reported adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with Medically attended AEs (MAAEs), new-onset chronic illnesses (NCIs), and serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of major neurologic complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in size of Oral Ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Recovery of oral mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of patients who have achieved complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who have achieved partial response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants enrolled in the study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of participants who complete the study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants who complete all the assessments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants who adhere to treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Segmental body fat percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in level of exertion during physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Irritable Bowel Syndrome Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of measurements
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Detection rate of preoperative contrast-enhanced spectral mammography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects achieving WBCT ≤120% of baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of the tampon-assay combination & LBC assay combination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative sensitivity of the tampon-assay combination vs the LBC-assay combination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Algorithm development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in American Shoulder and Elbow (ASES) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Days to COVID-19 vaccination
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Potency of LRRK2 inhibitors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum plasma cetirizine concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the plasma drug concentration versus time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal Function Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of mean root coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Cardiovascular mortality or hospital readmission
Endpoint domain: Mortality/survival
Primary endpoint: Sodium percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Knee Visual Analogue Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Chronic Postsurgical Pain (CPSP)
Endpoint domain: Adverse events/effects
Primary endpoint: number of oocytes retrieval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Mean score of individual subjective rating of social connection
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Cough severity index score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cough-specific quality-of-life questionnaire score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: DCIVA at 66 cm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects mildly symptomatic or less
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: children pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AD related biomarkers in tear fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AD related biomarkers in dry blood spots
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental status assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants with target vessel revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Patients' knowledge, skills, attitudes and behaviours regarding COPD management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Gamma camera-based whole-body 99mTc-ZHER2:41071 uptake value (% per organ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SPECT/CT-based 99mTc-ZHER2:41071 uptake value in tumor lesions (kcounts)/SUV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pore Volume in the Cheek Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Sebum Level in the Forehead Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Ease of Spinal Positioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluidity of the upper limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree and location of platelet activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postprandial plasma glucose area under the curve (iAUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial plasma insulin iAUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Transfusion independence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Gross motor function classification system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight-Height scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentrations of SARS-CoV-2-Spike protein specific IgG antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Uptake of [18F]FNP-59 in adrenal glands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in anxiety ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in postsurgical pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in medication use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total SEFAS (self-reported foot and ankle score)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Appearance of facial wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Fat volume retention at 3 months post-op
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat volume retention at 6 months post-op
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat volume retention at 12 months post-op
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peri- and postoperative complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastro-esophageal reflux disease-Health related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Short Form questionnaire (SF-36) Health related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life